Claws, Disorder, and Conformational Dynamics of the C-terminal Region of
  Human Desmoplakin by McAnany, Charles E. & Mura, Cameron
Claws, Disorder, and Conformational Dynamics
of the C-terminal Region of Human Desmoplakin
Charles E. McAnany and Cameron Mura∗
Department of Chemistry, University of Virginia, Charlottesville, VA 22904, USA
E-mail: cmura@muralab.org
Phone: 1.434.924.7824. Fax: 1.434.924.3710
∗To whom correspondence should be addressed
1
In press (2016)
ar
X
iv
:1
60
6.
02
73
7v
1 
 [q
-b
io.
BM
]  
8 J
un
 20
16
Abstract
Multicellular organisms consist of cells that interact via elaborate adhesion com-
plexes. Desmosomes are membrane-associated adhesion complexes that mechanically
tether the cytoskeletal intermediate filaments (IFs) between two adjacent cells, creat-
ing a network of tough connections in tissues such as skin and heart. Desmoplakin
(DP) is the key desmosomal protein that binds IFs, and the DP•IF association poses
a quandary: desmoplakin must stably and tightly bind IFs to maintain the struc-
tural integrity of the desmosome. Yet, newly synthesized DP must traffick along the
cytoskeleton to the site of nascent desmosome assembly without ‘sticking’ to the IF
network, implying weak or transient DP···IF contacts. Recent work reveals that these
contacts are modulated by post-translational modifications (PTMs) in DP’s C-terminal
tail. Using molecular dynamics simulations, we have elucidated the structural basis of
these PTM-induced effects. Our simulations, nearing 2µs in aggregate, indicate that
phosphorylation of S2849 induces an ‘arginine claw’ in desmoplakin’s C-terminal tail
(DPCTT). If a key arginine, R2834, is methylated, the DPCTT preferentially samples
conformations that are geometrically well-suited as substrates for processive phospho-
rylation by the cognate kinase GSK3. We suggest that DPCTT is a molecular switch
that modulates, via its conformational dynamics, DP’s efficacy as a substrate for GSK3.
Finally, we show that the fluctuating DPCTT can contact other parts of DP, suggesting
a competitive binding mechanism for the modulation of DP···IF interactions.
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Introduction
Desmosomes mediate cellular adhesion— Desmosomes are inter-cellular junctions found
in epithelial and cardiac tissue.1–7 By connecting the intermediate filaments (IFs) of neigh-
boring cells, desmosomes create a network of adhesive structural interactions that impart
tensile strength and durability to these tissues. The general architecture of the desmosome
is shown in Figure 1. Desmosomes expose the extracellular regions of two transmembrane
cadherins, desmocollin and desmoglein, on the cell surface; these proteins bind the cadherins
of neighboring cells via Ca2+-dependent homo- or heterophilic interactions. The desmoso-
mal cadherins traverse the plasma membrane and bind two other key proteins, plakoglobin
and plakophilin, which in turn bind a large, essential protein known as desmoplakin (DP;
Figure 1). DP binds to the cytoskeletal IFs and, because the cytoskeleton spans the cytosol
of one cell and binds to other desmosomes (which in turn bind to other, neighboring cells),
this extended network of adhesive molecular contacts links together cells into tissues.
The IFs bind to DP’s three plakin repeat domains (PRDs), which correspond to residues
1960-2208 and are denoted PRD A, PRD B, and PRD C (Figure 1).2,8 The C-terminal PRDs
are connected to the plakin domain, in DP’s N-terminal region, via a fibrous rod (residues
1057-1945, central coiled-coil in Figure 1). The coiled-coil region is responsible for DP dimer-
ization and, ultimately, links an electron-dense region known as the outer dense plaque (near
the cell membrane) to the inner dense plaque (proximal to the IF network), across a span of
≈ 10-20 nm (Figure 1).4,9 The plakin domain of spectrin repeats (residues 178-883, leftmost
structure in DP in Figure 1)10 provides a relatively rigid N′-terminal connection that binds
to the plakophilin (PKP) and plakoglobin (PG) proteins, thereby helping target DP to the
desmosome.11 Plakoglobin binds to the intracellular regions of desmocollin and desmoglein,
denoted as the cadherin cytoplasmic regions (CCR) in Figure 1. Crystallographic structures
of PRDs have revealed a basic groove that can sterically accommodate IFs, suggesting that
as a potential mode of DP···IF interactions.8,10,12,13
Because desmosomes impart structural integrity and mechanical strength to cell···cell
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junctions, aberrant desmosome function underlies several diseases of the skin and heart.7 For
example, pemphigus is an autoimmune disease caused by antibodies to desmoglein,14 the DP
mutation S2594P is linked to Carvajal syndrome,15 and several DP mutations are associated
with the lethal heart disease arrhythmogenic right ventricular cardiomyopathy.15–17 Down-
regulation of DP has been linked to metastasis of tumor cells,18 and desmosome function
in cancer remains an active area of research.2 Several point mutations in the desmoplakin
C-terminal tail (DPCTT) have been examined previously,19–21 providing evidence that the
DPCTT region regulates DP•IF adhesion.
Include Figure 1 here.
Cellular adhesion by desmosomes is regulated by two principal mechanisms: (i) Ca2+-
dependent adhesion of extracellular cadherin domains21 and (ii) phosphorylation-dependent
adhesion of DP to IFs.7 During desmosome formation, DP must be translocated to the
desmosome along the cytoskeletal network, and therefore must bind only loosely to IFs.
Once DP reaches the desmosome and is properly localized, it binds more tightly to the IFs
in order to create stable and persistent intercellular connections in epithelial tissues (e.g.,
skin) and cardiac muscle. The IF-binding site of DP is required for normal desmosome
assembly in vivo, suggesting that DP transport occurs along IFs;22 however, the S2849G
mutation, which is in the DPCTT, causes DP to associate abnormally strongly with IFs,
thereby retarding desmosome assembly.22
Post-translational modifications alter the behavior of desmoplakin— Cell biologi-
cal and proteomic work suggest that assembly of the DP•IF adhesion complex is regulated by
specific post-translational modifications (PTMs) in DP, including phoshporylation at S2849
in the DPCTT.7,19 At least two kinases are suspected to phosphorylate DP: protein kinase
C-α (PKCα) and glycogen synthase kinase 3 (GSK3). PKCα binds to DP in the cytoplasm
and phosphorylates DPCTT to initiate desmosome assembly.23 Once S2849 is phosphorylated,
a second kinase, GSK3, further phosphorylates DPCTT in a processive manner.20 GSK3 is
a processive kinase that recognizes peptides with the sequence SXXXSPO3 and phosphory-
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lates the serine.24 Suitable substrates for GSK3 are generally those peptides that have been
already phosphorylated, and the processive phosphorylation cascade proceeds in a C ′→N ′
direction.24 While its cellular activity is regulated by various factors, GSK3 does not display
strong substrate specificity on its own.25,26 Recent in vivo studies20,27 have shown that the
S2849G mutation has the same effect on DP as does inhibiting PKCα or GSK3—namely,
DP binds IFs tightly as soon as DP is synthesized, slowing its recruitment to the assem-
bling desmosome. The site of these phosphorylation events (i.e., the DPCTT) features a
glycine/serine/arginine-rich region (GSRR) containing the sequence (GSRS)5GSRRGS.
In addition to the S2849G mutation, which exhibits deleteriously enhanced IF binding, an
R2834H mutation causes cardiac dysfunction in mice, and various other mutations in DPCTT
are linked to various disease states.27 The residue R2834 in the DPCTT is important because
its dimethylation (giving RMe22834) may serve as a molecular switch for the processive
phosphorylation of this region. Indeed, DPCTT is phosphorylated at multiple sites, and this
phosphorylation cascade is contingent on two PTMs: a phosphorylation (SPO32849) and
a methylation (RMe22834). Because the R2834H mutation clearly precludes the RMe22834
state, this mutant DPCTT is phosphorylated only at SPO32849, and therefore presumably
binds tightly (and gets stuck) to the IF network.20,27
As mentioned above, GSK3 generally exhibits low substrate specificity. The R2834H
mutation provides an interesting counterpoint to this trend. Since GSK3 binds DPCTT at
SPO32849 in order to phosphorylate S2845, it is surprising that a relatively minor change (a
point mutation), eleven residues away from S2845, prevents GSK3 from initiating proces-
sive phosphorylation.27 Therefore, the DPCTT also provides a useful system to explore the
structural and dynamical basis of GSK3 substrate recognition.
In addition to phosphorylation, mass spectrometry (MS) studies of DPCTT have revealed
multiple methylated arginine residues, with up to six methyls concurrently in the DPCTT.20,27
(In that case, three of the seven arginine residues in the DPCTT were dimethylated.) In cases
where a single arginine is dimethylated, some evidence indicates that both methyls are on the
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same nitrogen, yielding an asymmetric dimethylarginine residue.28 In DPCTT, methylation
appears to be necessary before GSK3 can initiate processive phosphorylation. Since their
initial discovery in the 1960s,29 methylated protein residues often have been found to occur
in serine-rich region (SRR) regions; indeed, such sequences serve as a common substrate for
methyltransferases.30–32 However, unlike phosphorylation, methylation is not known to be
metabolically reversible, at least not outside the context of histones.33 Apart from regulating
the phosphorylation cascade of DPCTT, any functional roles of these methylations remain
unexplored.
Arginine claws can structurally rigidify disordered regions— The DPCTT contains an
SRR which is multiply phosphorylated,27 but any structural and dynamical effects of PTMs
in the DPCTT remain unknown. The structural dynamics of heavily-phosphorylated SRRs
have been studied in other systems, and phosphorylation of SRRs is a common regulatory
mechanism in the Eukarya.34 A three-dimensional (3D) structure known as the arginine claw
provides a rationale for some of these interactions and effects.
The arginine claw (RC), a relatively recently-identified structural element of SRRs, was
first characterized35 in the C-terminal region of ASF/SF2, a protein involved in mRNA
splicing, spliceosome assembly, and mRNA nuclear trafficking.36 This protein is phosphory-
lated in an SRR, and this modification serves as a nuclear import signal. Fundamentally,
the compaction of a peptide region into an RC sequesters charged side-chains away from
the protein surface (Figure 2). Implicit-solvent molecular dynamics (MD) simulations of
a fully-phosphorylated (RSPO3)8 peptide35 initially revealed a compact structure, with one
phosphate group coordinated by the guanidinium moieties of several arginine residues. An
RC such as we find in the DPCTT (see below) is shown in Figure 2c, alongside an illustration
of the RC originally characterized by Hamelberg et al.35 in Figure 2d. Such structures as
shown in Figure 2d were found to stably persist over the 200-ns, fully-atomistic, explicit-
solvent MD simulations of the (RS)8 system.35 In multiply-phosphorylated SRRs, those
phosphate groups not involved in the RC are solvent-exposed, and this dynamically-varying
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surface exposure has been proposed as the recognition mechanism for nuclear import of a
serine/arginine–rich ASF/SF2 (this particular ‘SR protein’ is also known as SRSF1).35 NMR
studies of the ASF/SF2 system, as well as hPrp28 (another RNA-splicing–related system),
have complemented the results of MD simulations, demonstrating that the phosphorylation
of SRRs rigidifies the region.37 Further simulation-based studies of RCs showed that claw
formation allows the SRR of the lamin B receptor to bind to histones, despite the large
positive charges of both interacting proteins.38 Crystallographic studies of the RNA splic-
ing factor SF1 have also revealed a partial RC.39 As a final recent example, simulations
have detected a claw-like structure in the long-time dynamics of a small, apoptosis-related
intrinsically disordered protein (IDP) known as Noxa.40
Include Figure 2 here.
Simulations of disordered structural ensembles are not straightforward— MD
simulations41,42 have been used to examine SRRs, IDPs, PTMs and, to a lesser extent, the
interplay between these.37,43–51 The long timescales of conformational transitions and struc-
ture formation in SRRs has often prompted the use of relatively inexpensive implicit-solvent
models. However, continuum solvent models likely overestimate the electrostatic effects of
salt bridges in determining three-dimensional structure,52 and RC simulations performed
with implicit solvent models predict more compact structures than do analogous explicit
solvent simulations.35 Another important consideration is the force-field (FF) used to de-
scribe the potential energy landscape of a system. Modern FFs have been used to predict
protein structures, albeit with limited success;53 any FF shortcomings are exacerbated in
simulations of IDPs due to the small energy differences between conformations.54 Recent
work has shown that CHARMM36 and ff03* predict substantially different secondary struc-
tures in glycosylated IDPs.50 Simulations of highly-charged systems are also affected by the
inadequate representation of electronic polarizability in current FFs. The classical Coulomb
model of electrostatic interactions has been extended to include polarizability, though polar-
izable FF parameters are not yet available for PTMs such as in the systems studied here.55
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FFs are generally parameterized against the physicochemical properties of well-characterized
model systems, for which experimental data or high-level quantum mechanical calculations
are available.56,57 Disordered peptides are often underrepresented in these parameterization
processes, as validating a structural ensemble generated by simulations of an IDP may be
experimentally challenging (versus non-IDP systems).51 Not only are structural parameters
difficult to determine experimentally,58 trajectory analysis is seldom straightforward and
many complex techniques have been employed in analyzing IDP simulation results.59 Fi-
nally, note that the RC is a somewhat unusual system insofar as it has a highly-charged
core, while FFs are parameterized against the more common cases wherein charged residues
are solvent-exposed. For these reasons, we note that simulations of systems of this type
should be considered more suggestive and predictive rather than conclusive.
For slow processes and rare events, the computational cost of simulating a system such
as an IDP for a sufficient length of time may be untenable. Several enhanced sampling
methods have been developed.60–62 However, the size of the DPCTT, with its extended starting
conformation (and requisite number of solvent molecules; Figure 2a), necessitates a large
number of replicas for replica-exchange simulations, and correspondingly long trajectories
are required for adequate mixing63 of the replicas (McAnany & Mura, data not shown).
Our MD simulations of DP— We used classical, all-atom MD simulations to examine
the structural effects of PTMs in the DPCTT, with a specific aim of elucidating the confor-
mational dynamics of this 70-residue region (Figure 1) and the riddle of strong/weak DP···IF
interactions (might DPCTT be a PTM-modulated molecular switch?). To mitigate the effects
of FF inaccuracies and limited sampling, each system was simulated under two independent
FFs (from the Amber and CHARMM families), and each production trajectory is at least
100-ns long. Simulations were extended to 200 ns for all phosphorylated systems; for consis-
tency in scaling the figures, the 200-ns simulations were split into 100-ns chunks. When we
refer to a simulation without explicitly mentioning a time, we refer exclusively to the first
100 ns; when referring to the second 100 ns, we call this ‘cycle2’.
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We begin by proposing a quantitative definition of an RC, and we show that simultaneous
methylation and phosphorylation cause DPCTT to assume conformations that are compatible
with GSK3–binding. We propose that DPCTT, in its various claw and non-claw states, com-
petes with IF molecules for binding sites on the neighboring PRD elements (Figure 1), thus
suggesting a straightforward dynamical mechanism for the regulation of DP···IF interactions.
Methods of Procedure
Molecular dynamics simulations
Classical, all-atom MD simulations were performed using NAMD 2.9,64 with either
the Amber PARM99SB65 or CHARMM3666,67 force-field. Parameters for modified
residues, such as diprotic phosphoserine (SPO3), were drawn from68 and69 as avail-
able (see below). No crystallographic or NMR structure of the DPCTT is avail-
able, so the peptide 2802LLEAASVSS KGLPSPYNMS SAPGSRSGSR SGSRSGSRSG SRSGSRRGSF
DATGNSSYSY SYSFSSSSIG H2871 was constructed using VMD’s Molefacture plugin in pro-
tein builder mode (VMD v1.9.1);70 note that the above sequence numbering matches human
DP (UniProt ID P15924), and the simulated DPCTT peptide ends at the very C ′-terminus
of DP. The peptide was constructed in an extended conformation (φ = 180◦, ψ = 180◦),
as shown in Figure 2a. PTMs were applied to specific residues (Figure 1) by using either
leap (for PARM99SB, LEaP from AmberTools1365) or patches in VMD’s psfgen tool (for
CHARMM36). Each initially-extended peptide system was subjected to a brief conforma-
tional relaxation simulation in implicit solvent. These relaxation simulations were performed
with rigid hydrogen atoms, a nonbonded cutoff distance of at least 11.0 A˚, and a Langevin
thermostat set to human physiological temperature (310 K). NAMD’s generalized Born im-
plicit solvent model71 was used with an ion concentration of 0.15 M. A 2-fs integration
timestep was used in all simulations. The relaxation simulation consisted of 10,000 steps of
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conjugate gradient potential energy minimization, followed by 10 ns of unrestrained MD. A
representative relaxed structure is shown in Figure 2b.
Periodic boundary conditions were set-up by solvating the final structures from the relax-
ation simulations in a truncated octahedral cell of water molecules, of sufficient dimensions
such that there would be at least 15 A˚ of water between the peptide and the envelope of
the cell (this worst case scenario being reached if the peptide were to adopt the most ex-
tended state found in the last 5 ns of the relaxation simulation). This heuristic was adopted
because of the periodic boundary conditions used in the explicit-solvent simulations: the
peptide will be flexible during the production runs, and any prolonged violation of a 30 A˚
distance between periodic images of the DPCTT solute could introduce artifacts. To miti-
gate computational costs, a “worst case” expanded size for the peptide was estimated based
on the last half of the relaxation run; the first half of the relaxation run was not used in
our geometry calculations, as the peptide is still collapsing during that time from its initial
(extended) state. Even with the relaxation simulation, most of our simulated systems still
contained over 200,000 particles (mostly H2Os). Waters were placed about the compactified
peptide using the SOLVATE program,72 with custom modifications introduced in-house to
enhance its performance. Ions were placed by VMD’s Autoionize plugin (for CHARMM36)
or LEaP (for PARM99SB) to reach 0.15 M NaCl. Because LEaP’s ion placement was ob-
served to be non-random, a 10-ns water equilibration run was performed on those systems
simulated using PARM99SB; this run comprised 100 steps of energy minimization, followed
by 10 ns of dynamics with the protein atoms harmonically restrained by a force constant of
1 kcal/mol/A˚2. All other parameters were the same as in the equilibration runs.
For consistency, all PARM99SB and CHARMM36 systems were equilibrated in the same
way, using the general approach of Mura & McCammon.73 Again, a 2-fs timestep, with at
least an 11.0 A˚ nonbonded cutoff and a 310 K Langevin thermostat, were used. Periodic
boundary conditions were employed with particle mesh Ewald (PME) electrostatics and a
grid spacing of better than 1/A˚ per direction. NAMD’s langevinPiston feature was used to
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maintain pressure at 1 atm. Protein atoms were initially harmonically restrained by a 50
kcal/mol/A˚2 spring. The systems were minimized for 1000 steps, then gradually heated in 10
K increments, with 2 ps of dynamics at each new temperature. Once the system temperature
reached 310 K, the restraints were weakened to 0.01 kcal/mol/A˚2 by repeatedly halving the
restraint strength and simulating for 2 ps. Finally, the restraints were completely removed
and the system was equilibrated for 10 ns in the NPT ensemble.
Production trajectories were computed using the same simulation parameters as the
equilibration runs described above, and were extended to at least 100 ns each (Table 1).
Analyses were performed using VMD and custom scripts written in the Python74 and D75
languages. All simulation and analysis scripts are available upon request, as are dehydrated
trajectories.
Methylarginine parameterization
Parameters for dimethylarginine, RMe2 , in the CHARMM family of FFs were generously
contributed by the Dejaegere laboratory.76 These parameters lacked a term for the CK1–
NH1–CK2 angle, subtended by the carbons of the added methyl groups and the nitrogen
to which they are bonded; therefore, the value of this term was estimated using ab initio
quantum mechanical calculations on a single RMe2 residue. Specifically, the GAMESS77,78
program was used to perform geometry optimizations at the RHF/3-21G level in implicit
water.79 First, the optimal equilibrium geometry was determined, then the relevant bond
angle was constrained 1◦ higher than the equilibrium angle and the equilibrium geometry
re-calculated subject to this constraint. The derivative of energy with respect to angle
provides the necessary value for this new FF parameter. The angle constraint was found to
be 95.467 kcal/mol/rad2, with an equilibrium angle value of 115.252◦.
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Analysis pipeline
For the sake of data-processing consistency, comparability, and automation, software tools
were developed into a pipeline to analyze each simulation trajectory in a standardized man-
ner. The detailed results of these analyses are shown in Figures S1 to S19. Figures were
prepared using matplotlib and Python 3.3, with some analysis steps performed in VMD and
the D programming language. Detailed descriptions of our analysis modules follow in the
remaining subsections.
Arginine clawicity, CyR∗ (panel a)— Plots of the arginine clawicity, arginine clawicity
(CyR∗ ), show, at each trajectory time-step, the CyR∗ of the simulated system. For each residue
in the sequence, the number of hydrogen bonds made to arginine are calculated, and the
largest of these numbers (the CyR∗ , by definition, where the ‘*’ wildcard denotes any residue)
is plotted as a blue point. A green trace, representing a 1-ns running average, smoothens
the noisy behavior of CyR∗ . On the right of the panel, a vertically-oriented histogram shows
the distribution of CyR∗ values over the entire simulation; an example is given in Figure 3a.
These histograms (e.g., ) are also used within the text to succinctly convey the CyR∗
behavior of a given simulation.
Residue-specific arginine clawicity, CyR (panel b)— Plots of residue-specific arginine
clawicity (CyR) show which residues are contained in an RC, as exemplified in Figure 3b.
For each residue, at each time-step, the number of hydrogen bonds to arginine is calculated.
These data are averaged with a 1-ns window before plotting, in order to avoid aliasing.
White areas indicate that no hydrogen bonds were made to arginine by a particular residue
at a particular time. For clarity, the DPCTT sequence is staggered (up/down) along the
horizontal axes of these plots: Residues on the top line align with inward-facing ticks and
residues on the bottom line align with the extended outward-facing ticks. The key residues
H2834 and S2849 are marked with asterisks.
SASA of residues 2849 and 2834 (panels c and d)— Solvent-accessible surface areas
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were calculated using VMD’s SASA tool, with a solvent probe radius of 1.4 A˚. As with CyR∗ ,
the solvent-accessible surface area (SASA) for each frame is shown as a blue point and a
green trace shows a 1-ns running average. SASA values were calculated for the entirety of
a residue, so comparison between systems with different residue modifications or mutations
requires caution, as the residues are of different size. The histogram adjoined to the right
axis (200 bins) shows the distribution of SASA over the entire simulation.
The S2849·····S2845 distance (panel e)— For each frame in the simulation, the distance
between the hydroxyl oxygens of S2849 and S2845 was calculated and plotted as a blue point.
The green trace shows a 1-ns running average, and the histogram on the right (200 bins)
shows the distribution of distances for the entire simulation.
GSK3 clash scores (panel f)— The GSK3 steric clash scores were evaluated via what
effectively became a one-dimensional docking procedure (Figure 5). We began with the 3D
structure of GSK3, taken as chain A from PDB entry 1I09.24 The (side-chain) oxygen of
residue 338 of chain B (the recognition site landmark), and the solvent-facing oxygen of the
phosphate docked to chain A (the active site landmark), were used as reference points for
alignment. These two reference points correspond to the recognition site and active site of
GSK3. Note that only those chain A protein atoms built into the crystal structure were
considered in the evaluation of clash scores. The corresponding pair of atoms from DP
are the side-chain oxygens of S2849 (phosphorylated prior to GSK3 interaction) and S2845
(destined for phosphorylation by GSK3). In phosphorylated systems, the oxygen attached
to the carbon was used. For each frame of each trajectory, DP and GSK3 were aligned based
on the two pairs of atoms described above. GSK3 was then rotated, in 1◦ increments, about
the axis defined from these four reference points. For each configuration, the number of
clashes was taken as the number of contacts between atoms in GSK3 and atoms in DP (sans
hydrogens for computational efficiency), with a 2 A˚ sweep radius. The minimum number
of contacts, considered among all rotated positions for the trajectory frame in question, is
13
defined as the clash score for that frame; it is this quantity which is plotted in the panels f.
Contact maps (panel g)— The contact map shows the pairwise contacts within a protein
3D structure, measured as a symmetric matrix of interatomic distances, di,j, for all pairs of
residues i and j. The distance is defined so as to account for side-chain interactions: for a
given residue pair, all pairs of atoms within each of the two residues (ix, jy) are considered,
where atom x (ix) is from residue i and atom y (jy) is from residue j. The contact map
distance for (i, j) is then taken as the distance between the closest pair of atoms for all
of those pairs within the residue pair. In our illustrations, the lower-left triangle of the
contact map shows the average inter-residue distance for the duration of the simulation,
while the upper triangle gives the minimum distance considered over the entire trajectory.
The horizontal axis is identical to that used for CyR, and the vertical axis is marked every
ten residues and at the residues that were PTM sites in this study (asterisks).
Ramachandran plots (panel h)— Ramachandran plots show the distribution of peptide
backbone torsion angles, (φ, ψ), for each system, along the entire trajectory. Colors are
graded by the logarithm of the probability density of a given (φ, ψ) configuration. Regions
corresponding to canonical secondary structures are demarcated by guidelines, with the
boundaries drawn from the MolProbity source code.80 The percent of observations in each
region is given at the top of the panel, and these regions roughly correspond to secondary
structures: ‘Lα’ = left-handed α-helix; ‘Lα+’ = generously-allowed left-handed α-helix; ‘e’
= Ô-turn regions, often found ahead of a helix or strand; ‘α’ = standard (right-handed)
α-helix; ‘β’ = β-strand; ‘g+’ = generously-allowed helix or strand; ‘o’ = other structures.
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Results
Arginine claws occur in the DPCTT
A claw can be quantitatively defined, and occurs in the DPCTT— Past efforts have
qualitatively detected RCs based on visual analysis of trajectories, such as the one shown
in Figure 2d.35,38 These past claws (i) were characterized as multiple arginines interacting
with a phosphate, (ii) were found to be stable on the timescale of a 100-ns simulation, and
(iii) had estimated free energies of formation of ≈ –5 kcal/mol.35 While those attributes
describe the behavior of a claw, they are not suitable metrics for determining the claw-
forming propensity across a number of trajectories, which is a goal in our current study.
First, the above set of descriptors does not, in and of itself, provide an algorithmic solution to
the decision problem of whether a particular structure is or is not an RC. Second, the above
description involves kinetic and thermodynamic information, both of which require more
computationally expensive calculations than would a straightforward geometric definition of
an RC. Finally, the above description of a claw does not work well for a trajectory that
transiently adopts a claw or claw-like conformation. Therefore, we propose a definition of a
claw that is akin to that of a protein secondary structural element.
Our definition is purely geometric, based only on a definition of the hydrogen bond,81,82
and our parameter is easily evaluated for an arbitrary 3D structure. We define the clawicity,
CyAB, as the maximum number of hydrogen bonds made by any residue in B to all residues in
A. For example, CyRS51 refers to the number of hydrogen bonds made by S51 to all arginine
(R) residues. CyRS refers to the number of hydrogen bonds made to an arginine by the serine
(any serine) with the greatest number of hydrogen bonds to arginine. We define the arginine
clawicity (CyR∗ ) as the number of hydrogen bonds made to arginine residues by the residue
with the most hydrogen bonds to arginine (here, the ‘*’ wildcard means any residue). The
residue-specific arginine clawicity (CyRi ) is defined as the number of hydrogen bonds made to
arginine by each residue, i. Thus, for a peptide containing n residues, CyR would contain n
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values: CyR1 , CyR2 , CyR3 , ..., CyRn−1, CyRn . In the current work, we consider a hydrogen bond
to have a donor·····acceptor distance below 3 A˚ and a donor–hydrogen–acceptor angle less
than 20◦. This definition is trivially extended to other residues and may be made smoother
by incorporating a definition of hydrogen bonds with non-integer order. For example, the
order of a hydrogen bond might smoothly decrease from 1 to 0 as the donor·····acceptor
distance varies from 3 to 4 A˚.
As an initial observation, note that representative plots of the arginine clawicity CyR∗
(Figure 3a) and the site-specific CyR (Figure 3b) reveal a rather strong RC when the R2834H
SPO32849 system is simulated under the CHARMM36 force-field.
Include Figure 3 here.
To facilitate communication in this text, we represent CyR∗ values using histograms as in-line
strip charts, e.g. . Each bar denotes the frequency of a particular CyR∗ value across
a trajectory, with the leftmost bar representing an CyR∗ of zero. For example, tends
to adopt structures of CyR∗ equal to 1, 2 or 3. Conversely, shows a system with a
particularly strong RC. Distributions of CyR∗ values for the last 100 ns of each simulation
system are shown in Table 1.
Table 1 NEAR HERE.
We discovered an RC in the conformational states sampled by the DPCTT, as shown in Fig-
ure 2. Several arginine residues in DPCTT surround SPO32849 and form numerous hydrogen
bonds and ion-pairs. Notably, some of the RCs found in the DPCTT are long-lived structures,
such as were those identified by Hamelberg et al.35 To our knowledge, DPCTT is the largest
unstructured peptide wherein an RC has been found.
Non-phosphorylated DPCTT systems do not form strong claws— The unmodified
(non-phosphorylated) wild-type DPCTT peptide does not adopt a strong RC, as shown in
Figures S1a and S2a for the Amber and CHARMM force-fields, respectively. Simulations
under PARM99SB show little RC formation ( ), and Figure S1b shows that no
residue consistently hydrogen-bonds with any arginine with an CyR exceeding unity. The
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simulations using CHARMM36 predict slightly higher average CyR∗ , , than do those
using PARM99SB. Amino acids D2851 and H2871 (the final C′-terminal residue) account
for most of the CyR∗ , as shown in Figure S2b.
As mentioned above, a newly-discovered PTM in the DPCTT is asymmetric dimethylation
of R2834, yielding RMe22834.27 For this modified peptide system, we find a slight increase
in the average CyR∗ when PARM99SB is used, . D2851 is the primary contributor
to this weak RC (Figure S14b). CHARMM36 predicts a slightly higher CyR∗ than that
seen in the unmodified peptide: . Consistent with the PARM99SB simulation of
this system, D2851 is the primary residue creating the RC in the CHARMM36 trajectories
(Figure S15b). This particular RC structure does not appear to be dynamically stable: it
briefly dissociates 40 ns into the trajectory, and then re-forms at ≈60 ns. This observation
suggests that, although a claw can form in this system, the DPCTT would be unlikely to
adopt a collapsed RC conformation as a stable, long-lived structure.
The R2834H mutant exhibits low CyR∗ values under PARM99SB ( ), with Fig-
ure S8b showing E2804 forming the center of a weak RC. Under CHARMM36, D2851 forms
no RC and the overall CyR∗ is low: . For R2834H simulations under both FFs, the
clawicity behavior is similar to that in the unmodified system.
The behavior of DPCTT is sensitive to force-field— The backbone dihedral angle
distributions for PARM99SB and CHARMM36 are shown in Figure 4. A recent method-
ological study of an arginine/serine (RS)-rich peptide (unrelated to DP), using several FFs,
found that CHARMM36 tends to favor the formation of left-handed helices.54 We found that
DPCTT, which also contains an SRR, does not show this trend, at least not on the timescales
of our present simulations. Instead, CHARMM36 frequently predicts more β-strand char-
acter (54.5%) than does PARM99SB (40.9%), as indicated in Figure 4. The total helical
content (including left-handed helices) is somewhat higher under PARM99SB (23.0%) than
it is under CHARMM36 (18.4%).
Include Figure 4 here.
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Site R2834H provides a striking example of the differential structural effects of vari-
ous FFs. In the phosphorylated R2834H system, PARM99SB predicts that H2834 will be
essentially entirely buried in the protein, or at least occluded from solvent (Figures S10d
and S11d). In contrast, CHARMM36 predicts that this residue will be solvent-exposed,
perhaps as a result of the constraints imposed by the strong RC that forms in this system
(Figures S12d and S13d). Similarly, in the methylated system, PARM99SB predicts a more
buried RMe2 (Figures S16d and S17d) than that predicted by CHARMM36 (Figures S18d
and S19d).
Phosphorylation of S2849 leads to claw formation in the wild-type system—
Trajectories computed under both CHARMM36 and PARM99SB are consistent, inasmuch
as the SPO32849 system (with no other modifications) frequently forms an RC. PARM99SB
predicts a substantial shift from the unmodified CyR∗ profile, . The SPO32849 system
adopts a high CyR∗ , , in the first 100 ns of the production run, followed by
in the next 100 ns (cycle2). Figures S4a and S5a indicate that this system’s DPCTT’s claw is
less stable than that reported for the (RS)8 peptide,35 and Figure S4a also shows a dramatic
re-structuring at ≈70 ns in the production run. CHARMM36 shows a similar trend, moving
from the unmodified CyR∗ ( ) to in the first 100 ns, and then in
the second 100 ns (cycle2). Figures S6a and S7a show a more stable RC, akin to that seen
previously.35 For both FFs, the RC that forms is centered around position SPO32849 (panels
(b) in Figures S4 to S7).
For comparative purposes, an additional simulation was performed with the monoprotic
phosphate modification, SHPO32849 (versus the diprotic SPO3), using the Amber FF. This
system, under PARM99SB, exhibited essentially no CyR∗ ( ). Figure S3b shows that
the RC does not form around SHPO32849 to any appreciable extent; instead, an aspartate
residue (D2851) makes occasional structures with CyRD2851 values of 2, and this tendency
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diminishes after ≈40 ns.
Methylation of R2834 weakens the RC— Simulations of the phosphorylated peptide
with PARM99SB show that methylation of R2834, in conjunction with the phosphoryla-
tion at S2849, significantly weakens the RC, with in the first 100 ns followed by
in the second 100 ns. The second cycle even has slightly lower CyR∗ than the
non-phosphorylated R2834H system. Figures S16b and S17b show that the principal residue
involved in the RC is still SPO32849. The effect predicted by CHARMM36 is more subtle: the
CyR∗ values remain similar to the non-methylated system in terms of their distribution, but
Figures S18a and S19a show that the RC is more labile in this system. The sliding-window
average (green trace) shows an increased variability compared to the nearly-constant behav-
ior seen in Figures S6a and S7a (compare also the panels (c) [SASA of S2849] in Figures S6,
S7, S18 and S19). Again, the CHARMM36 RC is centered on SPO32849 (Figures S18b
and S19b).
Mutation R2834H may disrupt the RC structure— For simulation systems containing
the R2834H point-mutant as well as phosphorylation at S2849 (i.e., SPO32849), the two FFs
give differing results. Specifically, PARM99SB predicts essentially no change from the non-
phosphorylated system in terms of CyR∗ , with for the first 100 ns and
for the next 100 ns; Figures S10b and S11b show that the RC stably settles at SPO32849
by the second half of the 200-ns trajectory. In contrast, the CHARMM36 simulation of this
system gives the strongest RCs observed in any of our trajectories ( for the first 100
ns, followed by for the remaining 100 ns), with the RC forming essentially near
the start of the trajectory. The running averages for CHARMM36 (Figures S12a and S13a)
reach clawicity values of 6, while no other simulation system ever reaches 5.
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RCs typically exclude solvent
Analysis of the solvent-accessible surface area (SASA) of SPO32849 can be used to reveal the
general solvation features (buried, partially exposed, or fully exposed) of the RC in a 3D
structure. The negatively-charged SPO3 residue will be electrostatically attracted to arginine
side-chains and, as expected, this is borne out in our observations of CyR∗ values. In those
simulation systems containing SPO32849 but not exhibiting an RC, one might expect that
the phosphate would be solvent-exposed and engaged in hydrogen bonds with water. We
find that, for the non-methylated systems, this model works well. In systems containing a
strong RC, a plot of the SASA of SPO32849 shows that the phosphoserine is buried within
the protein, as seen by comparing the (a) (RCy) and (c) (SASA) pairs of panels in Figures S4
to S7, S12 and S13, and note the anticorrelation between RCy values and the SASA. In the
PARM99SB simulation of the S2849-phosphorylated R2834H mutant, the CyR∗ was relatively
low in the first (Figure S10a) and second (Figure S11a) 100-ns bins, and this agrees with the
higher SASA observed for SPO32849 in Figures S10c and S11c; the negative correlation can
be seen here, again, most clearly by comparing the trend in Figure S10a (increasing values)
and Figure S10c (decreasing values). The monoprotic system, SHPO32849 under the Amber
FF, similarly shows low CyR∗ and high SASA values for SHPO32849 (Figure S3c); the SASA
values at this site are quite broadly distributed (Figure S3c, marginal histogram), implying
a structurally heterogeneous ensemble of conformational states.
The methylated systems present two deviations from this inverse trend between CyR∗
and SASA values. Under PARM99SB, SPO32849 interacts with non-arginine residues on
the protein surface, in the methylated system. In Figure S17c, the SASA of SPO32849 can
be seen to jump from a buried state to an exposed state after 40 ns, with no concomi-
tant change in the CyR (Figure S17b). SPO32849 interacts with S2861 and S2835 until 140
ns in the production trajectory, at which point it disengages from these residues while re-
maining attached to R2838 (until 197 ns). When the methylated system is simulated using
CHARMM36, a solvent-exposed RC forms. The phosphate is clearly solvent-exposed, as
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shown in Figures S18c and S19c, but this system still forms an RC ( ).
Methylation and phosphorylation prime DPCTT for GSK3 activity
The DPCTT sequence (Figure 1) contains several potential phosphorylation sites, including
consensus sites for the GSK3 kinase. Recent experiments have revealed that DP is phospho-
rylated in its CTR by GSK3.27 Thus, we used two simple metrics to assess the ability (not
necessarily the propensity) of the DPCTT to interact with GSK3 throughout the entire MD
trajectory: (i) the SPO32849·····S2845 distance, and (ii) the extent of steric clash between the
DPCTT and GSK3 molecules. First, the simple geometric distance between SPO32849 and
S2845 was measured and compared to the distance between the recognition site and active
site in GSK3. This distance was used because SPO32849 maps to GSK3’s recognition site and
S2845 corresponds to the kinase’s active site. In the GSK3 crystal structure,24 this distance
is ≈ 12 A˚ (some variability in this value is expected, as the active site was not occupied by
a substrate in this GSK3 structure). As a rudimentary gauge of DPCTT’s ability to bind to
GSK3, we suggest that DPCTT conformations wherein the SPO32849·····S2845 distance is ≈
12 A˚ will be more favored to bind to GSK3 as a result of simple geometric matching, without
requiring substantial structural rearrangement of the DPCTT.
While DPCTT systems that are not phosphorylated at S2849 would not be expected (bio-
logically) to interact with GSK3, it is nevertheless informative to consider, as a background
distribution, how these distances compare for the non-phosphorylated and phosphorylated
systems. We find that the distances in the non-phosphorylated systems show a strong depen-
dence on FF. PARM99SB yields distances that are substantially less than 12 A˚ for the com-
pletely unmodified wild-type system (Figure S1e) and the methylated, non-phosphorylated
wild-type system (Figure S14e). The non-phosphorylated R2834H mutant system starts
with GSK3-compatible distances, but collapses at ≈ 70 ns to incompatible distances (Fig-
ure S8e). In general, the CHARMM36 simulations predict longer distances than PARM99SB,
and tend to predict distances that are more compatible with GSK3 binding (see Figures S2e,
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S9e and S15e).
Simulations of the phosphorylated DPCTT systems exhibit good agreement between the
distance distributions for PARM99SB and CHARMM36. Our distance parameter consis-
tently lies between ≈12–15 A˚, which is compatible with GSK3 binding. The R2834H mu-
tation in the phosphorylated system leads to a slight decrease in the distance under both
PARM99SB and CHARMM36 (panels (e) in Figures S10 to S13), compared to that seen in
the other two phosphorylated wild-type systems—namely, (i) the phosphorylated (SPO32849)
system in panels (e) of Figures S4 to S7, and (ii) the phosphorylated & dimethylated systems
(SPO32849 & RMe22834) in panels (e) of Figures S16 to S19.
Our second GSK3-compatibility criterion, described in Figure 5 and in the Methods sec-
tion, assesses the ability of GSK3 to sterically accommodate various structural states of
DPCTT. Specifically, we align (i) the active site of GSK3 with S2845 of DPCTT (as this
is where the next phoshporylation event will occur), and (ii) the recognition site of GSK3
to SPO32849 (as this is the landmark in DPCTT that is recognized). These spatial trans-
formations and geometric constraints effectively reduce the problem to a one-dimensional
protein•protein docking exercise, the one degree-of-freedom being rotation about the line
defined by constraints (i) and (ii); this construction is schematized in Figure 5. If there
exists a rotation wherein GSK3 and DPCTT can be brought together without substantial
steric clash (literally, overlap of atomic van der Waals envelopes), then this suggests that
GSK3 can readily bind to that conformation of DPCTT (or at least that there is no en-
thalpic barrier to doing so). By this measure, we find that the only phosphorylated DPCTT
systems which exhibit steric compatibility along the trajectory frames are the methylated
systems (Figures S17f and S19f). This accommodation is seen with both the PARM99SB
and CHARMM36 FFs in the last 50 ns of the production run. Therefore, based on these
data we suggest that methylation at R2834, yielding RMe22834, ‘primes’ DPCTT for pro-
cessive phosphorylation by biasing its structural ensemble towards conformations that are
amenable to GSK3 phosphorylation.
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Include Figure 5 here.
The serine-rich region of DPCTT is not entirely free in solution
Potential interactions between the SRR of the DPCTT and the rest of the large DP protein
(Figure 1) were explored by analyzing pairwise inter-residue distances. As detailed in the
Methods section, the full suite of contact maps, shown in panels (g) of Figures S1 to S19,
give the mean inter-residue distances (lower triangle), averaged over entire trajectories, while
the upper-right triangle gives the minimum inter-residue distance across an entire trajectory.
One may be tempted to view the DPCTT as a disordered string that thermally fluctuates
in solution, but this is not entirely accurate: the dynamical DPCTT may in fact double back
on the plakin repeat domains (as a reminder, see the PRDs in Figure 1). While simulations of
larger DP systems, including an entire PRD in addition to the DPCTT, are beyond the scope
of this work, the first few residues of our DPCTT simulation system are from a PRD (the
third PRD in Figure 1). Therefore, if the phosphorylated SPO32849 samples conformations
that bring it near the first few residues of DPCTT, then that suggests that regions within the
DPCTT may interact directly with the PRDs to regulate IF binding (and also that simulations
limited to only the SRR might not account for all the factors that govern the structure and
dynamics of this region). In all of our simulations, the SRR comes into close spatial proximity
to other regions of DPCTT, including the more N′-terminal residues that are part of PRD-
C. A possible mechanism by which the DPCTT can attenuate the overall strength of DP•IF
binding may involve a simple binding competition between IFs and DPCTT for the IF-binding
site of the plakin repeat domain; in this model, the precise pattern of PTMs, and therefore
the clawicity and dynamics of the DPCTT, would modulate the competitive binding events.
When DPCTT is fully phosphorylated, its strongly negative charge could compete with the
(negatively-charged) IFs for the binding groove on the PRD, as suggested by crystallographic
studies.8,10,12
Include Figure 6 here.
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Discussion
Arginine claws can form in partially phosphorylated systems— Past work on the
arginine claw considered only fully-phosphorylated (RS)n repeats.35,38 To our knowledge, our
present study provides the first evidence that RCs can form in other systems too. Experimen-
tal and computational studies of a 36-residue peptide from myelin basic protein suggested
that phosphorylated threonines can confer structure to disordered regions, via electrostatic
interactions with basic residues. However, unlike an RC, the interactions in that system did
not result in burial of the phosphate group within the protein.47 Our present simulations,
focused on the DPCTT, predict that a strong RC can form in protein segments with only
half the arginine density of RS-repeat peptides, and even when only a single serine is phos-
phorylated. Therefore, the RC may be a common, or at least underappreciated, structural
element in phosphorylation-based regulation of protein function via molecular switches, even
for protein sequences that lack canonical (RS)n repeat regions.
Claws are predicted by several force-fields— The original RC was described as “very
stable and, once formed, persist[ing] for the rest of the simulation”;35 that initial study
employed only the Amber FF03 parameter set. A subsequent study of another RS-rich
peptide found that RCs form under the Amber PARM99SB-ILDN FF.38 Our simulations of
DPCTT show that RCs can form under both PARM99SB and CHARMM36. Nevertheless,
the fine details of RC dynamics are sensitive to the FF; for instance, for many of our systems
CHARMM36 frequently predicts higher CyR∗ values than does PARM99SB.
The FF-dependence of our CyR∗ parameter is substantial, and this may reflect the some-
what unusual chemical nature of RC sequences, versus most protein sequences. In addition
to charged moieties buried in a proteinaceous core, arginine···phosphate interactions are
characterized by a “covalent-like” stability83 that may be only inadequately described as
point-charges interacting via simple Coulombic electrostatics. An RC was not detected in
recent NMR experiments with another RNA splicing-related, serine/arginine-rich system;37
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however, the structural ensembles reported in that work were derived via an approach (a
‘sub-ensemble selection procedure’ against the NMR data) differing from the simple, naive
equilibrium MD simulations reported here and elsewhere,35,38 and the trajectories in that
work sampled shorter (≈50-ns) timescales. In short, it remains to be established if RCs
occur in solution, and under what conditions. A recent crystal structure has shown that
(solvent-exposed) RCs can form in the RNA splicing factor SF1.39 In that system, the RC
acts as a secondary structural element in an otherwise disordered region; notably, electron
density could be detected for residues immediately upstream of the phosphoserine, but only
in the phosphorylated, not the non-phosphorylated, system.39
Methylation in the DPCTT may promote GSK3 binding— From the simulations
presented here, we suggest that the RMe22834 and SPO32849 PTMs are required for produc-
tive DP···GSK3 interactions. This claim is based upon three lines of evidence. First, our
modified DPCTT systems were found to present the phosphate group on the surface, rather
than buried within the protein. This surface exposure did not occur in phosphorylated sys-
tems with unmodified R2834, suggesting that methylation is coupled to the dynamics of
SPO32849 accessibility. As the processive kinase GSK3 recognizes proteins already contain-
ing a phosphate, exposure of SPO32849 may facilitate GSK3 binding. Second, we find that
in some trajectories the SPO32849·····S2845 distance closely matches the distance between
the active site and substrate recognition site of GSK3. Upon GSK3 binding to SPO32849,
S2845 can reach the active site of GSK3 without DP having to undergo conformational
changes. Third, the steric clash (Figure 5) between DP and GSK3, computed along entire
trajectories, is far lower in systems containing RMe22845 than in those without this PTM.
The degree to which DP must deform to bind to GSK3 is therefore much lower, increasing
the probability that contact between DP and GSK3 leads to the addition of a phosphate
at S2845; that is, PTMs may help ‘pre-structure’ the DP substrate in a binding-competent
state, thereby decreasing the entropic cost associated with forming a DP•GSK3 complex. In
our mechanistic model for GSK3 regulation, DPCTT essentially self-regulates its processive
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phosphorylation by GSK3; DPCTT achieves this by sampling conformational states that vary
in their suitability as substrates for GSK3.
The serine-rich region of DPCTT contacts other parts of DP— Past studies of
RCs have examined short, (RS)n–containing peptides in isolation. The serine-rich region
of DPCTT is not well-described by these past models, as we have shown that the SRR can
interact with other regions of DP. In particular, the SRR can contact residues that have
been resolved in a crystal structure of a plakin repeat domain.8 The charge-complementarity
between a fully-phosphorylated SRR in DPCTT and the positively-charged IF-binding groove
on a PRD,8 combined with the tendency for DPCTT to explore the surface of DP, suggests
that a simple competition for PRD binding sites may account for the cellular effects of DPCTT
phosphorylation. That the DPCTT is covalently linked to the upstream PRDs (Figure 1)
implies a high local density of negative charge, and this could compete with the negatively-
charged IFs to cause DP to detach from the IF network; examination of the ionic strength-
dependence of this process would be telling. Finally, note that in our mechanistic model
any structural role for arginine claw conformational dynamics (apart from its role in GSK3
processive phosphorylation) would require a further series of simulations, ideally including
as many structured PRD regions as possible.
Conclusion
Recent experiments have revealed that desmoplakin’s activity is regulated by PTMs in its
presumably-disordered C-terminal tail. Using MD simulations, we have elucidated the struc-
tural effects of three modifications in the 70-residue DPCTT region: phosphorylation of S2849,
methylation of R2834, and mutagenesis of R2834 to histidine. Our simulations indicate that
an RC can form in some of the phosphorylated systems, sequestering the phosphate within
the protein. To our knowledge, DPCTT is the largest system that has been shown to form an
RC by MD simulation. Our findings build on past studies of RC formation in SR repeats,
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and are corroborated by recent crystallographic results for other SR systems. Upon methy-
lation of R2834, the SPO32849 phosphosite becomes solvent-exposed, which may enhance its
detection by the cognate kinase GSK3. Methylation of R2834 has the further effect of biasing
the structural ensemble towards conformations that are sterically compatible as substrates
for GSK3.
We also find that the DPCTT’s SRR is not isolated from the rest of DP, suggesting that
studies of short peptides excised from larger systems may miss some of the interactions that
define the conformational ensemble of such regions. This point is illustrated by the effects
of R2834 methylation: The position of the RC, and the overall conformation of the DPCTT,
are affected by this seemingly minor chemical modification, many residues away from the
site of phosphorylation. The common self-contact in DPCTT, seen in contact maps for all
our simulated systems, suggests that a regulatory mechanism of DP···IF adhesion may be
a simple binding competition between DPCTT and the IFs for the positively-charged groove
on plakin repeat domains.
By elucidating the roles and linkages between protein conformational dynamics, PTMs,
and claw-like structural elements, our simulations of the C-terminal region of human desmo-
plakin synthesize several strands of evidence and shed light on the underlying molecular
mechanism of DP···IF interactions, including the riddle of strong/weak interactions with
the IF network. We predict that RCs can form when S2849 is phosphorylated, and that
methylation of the disease-associated site R2834 promotes processive phosphorylation by
GSK3. Our data also are consistent with DPCTT binding to a PRD, thus providing a simple,
atomically-detailed competition mechanism for the regulation of DP•IF adhesion.
Associated Content
Supporting Information — Detailed results of the analysis suite described in the Methods
section of the main text, as applied to each of our simulation systems. Each trajectory has
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been analyzed in terms of (a) CyR∗ , (b) CyR, (c) SASA of S2849, (d) SASA of R2834, (e) the
S2849·····R2834 distance, (f) GSK3 steric clash scores, (g) inter-residue contact maps, and
(h) the distribution of peptide backbone torsion angles (φ, ψ).
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Figure 1: Desmoplakin in context: Architecture of the desmosome. Key components of the
desmosome are diagrammed here, with the length of each rectangular protein schematic corresponding to
the number of amino acids (scale bar, lower-right). Dsg and Dsc are the transmembrane cadherin proteins
desmoglein-1 and desmocollin, respectively; plakoglobin (PG) and plakophilin (PKP) are adapter proteins
that bind the N′-terminal region of desmoplakin to the cadherin cytoplasmic regions (CCR) of Dsg and
Dsc, as indicated. The PG crystal structure is inset,85 as are the structures of PKP84 and two PRDs.
DP is shown in the middle, and regions of known structure are inset.8,10 Crystal structures are drawn
as ribbon diagrams, with the color graded from the N′ (blue) to C′ (red) terminus. The locations of the
R2834 and S2849 modifications in the DPCTT sequence are marked. Our various DP simulation systems
included: (i) the unmodified, wild-type sequence of DPCTT, (ii) the wild-type sequence phosphorylated at
S2849, (iii) the wild-type sequence methylated at R2834, (iv) the wild-type sequence phosphorylated at
S2849 and methylated at R2834, (v) the R2834H mutant, and (vi) the R2834H mutant phosphorylated at
S2849. All phosphate PTMs were diprotic, with the exception of one test system containing a monoprotic
phosphoserine. (See also Table 1.)
Figure 2: A recognizable RC in the DPCTT. All simulation systems started in an extended backbone
conformation (with bends at each proline residue), as exemplified in (a). After 10 ns of implicit-solvent
simulation under CHARMM36, the R2834H S2849SPO3 system can be seen to have collapsed and formed
an RC (b). A sample RC, at 95 ns for the R2834H S2849SPO3 system under CHARMM36, is shown in
(c). The gray surface surrounds all residues other than arginines (shown as bonds), and the SPO32849
phosphosite is explicitly shown (ball-and-stick). Hydrogen bonds are represented as dashed orange lines.
For reference, an RC previously identified in an unrelated system35 is shown in (d), rendered similarly as
in (c); the coordination geometry of arginines and a phosphoserine is similar to that seen for the DPCTT
in (c). The structural stability of an RC is demonstrated in (e) by overlaying multiple frames from the
simulation trajectory of (c). The regions near the RC remain stable for the duration of the simulation, with
the chelating arginines (shown as bonds) moving very little relative to SPO32849 (ball-and-stick, only oxygens
can be seen). The rest of the DPCTT backbone (thin ribbons) does not adopt a single, stable structure.
Figure 3: Representative results from the analysis pipeline, showing a strong RC. The CyR∗ for
the first 100 ns of the R2834H S2849SPO3 simulation under CHARMM36 is shown in (a), demonstrating the
appearance of a strong claw (large, persistent clawicity value). Blue points show the arginine clawicity, CyR∗ ,
defined as the number of hydrogen bonds made to arginines by the residue with the most hydrogen bonds
to arginine; the green line is a 1-ns running average. The marginal distribution on the right is a histogram
of piled-up CyR∗ values, ranging from 0 to 8: . The residue-specific CyR (b) shows that CyRS2849
frequently exceeds 6, and that only D2851 (immediately to the right of the dark strip) makes any other
substantial contribution to this system’s CyR∗ .
Figure 4: Backbone conformations across all simulations. To gauge the frequency of any unusual
(non-canonical) secondary structures, Ramachandran plots are shown for all of our (a) CHARMM36 and
(b) PARM99SB data, compiled across all trajectories for all simulation systems. Regions corresponding to
canonical secondary structural elements are indicated as countour lines (see also the Methods section), and
the color-scale is graded by the log-likelihood of a particular (φ,ψ) conformation. In contrast to a recent
report,54 we find that DPCTT does not show a preference for left-handed helices under CHARMM36; those
recent simulations of a non-phosphorylated SRR, unrelated to our DP systems, found that CHARMM36
predicts that over 40% of the residues in the simulated peptide are in left-handed helices, even though only
≈ 6% of the residues in a reference set of known protein structures exhibit such a structure. Our CHARMM36
trajectory data do not indicate that left-handed helices are a problem, at least in our simulation systems.
Combining all frames of every simulation, CHARMM36 predicts 9% left-handed helix, while PARM99SB
predicts 7%.
1
Figure 5: A method to evaluate potential DP···GSK3 geometric complementarity via one-
degree-of-freedom docking. We begin with two molecules to be docked, as schematized in (a). Say we
know that the red atom on the yellow molecule aligns with the red atom on the blue molecule when the
molecules interact. (In this two-dimensional case, only one atom is needed per molecule; in three dimensions,
two atoms per molecule are needed to define an axis of rotation.) In step (b), the molecules have been aligned,
in arbitrary angular orientation, based only on the positions of their red atoms. Next, the yellow molecule is
rotated about the axis defined by the red atoms (c). At each step in the full rotational sweep (1◦ increments
in our implementation), the clash score is computed as the number of pairs of atoms (one from DP, one
from GSK3) with an interatomic distance less than 2 A˚. The best pose (d) is taken as the one with the
minimal clash score. This procedure is repeated for each frame along the trajectory. In a realistic example
(e), two atoms (red, orange) from GSK3 are used to perform the alignment. The outward-facing oxygen of
the phosphate (orange sphere) defines the recognition site, while the active site is defined by the side-chain
oxygen of S261 (red sphere) of chain B (gray ribbon). The protein atoms from chain A (dark surface) were
used to calculate the clash. The atoms in DP that were used to perform the alignment are highlighted in (f).
This frame, from 173.48-ns in the production trajectory of RMe22834 SPO32849 (CHARMM36), has a very
low clash score of 18; all non-hydrogen atoms from DP (dark surface) were used to calculate the clash. The
side-chain oxygen of S2845 (red) will be phosphorylated by GSK3 only if S2849 (orange) is phosphorylated.
Note that the three terminal oxygens of the phosphate are still engaged in an RC (hydrogen bonds in orange).
Figure 6: S2849 in close proximity to the PRD. This frame, from 71-ns in the R2834H, S2849SPO3
simulation under PARM99SB, exemplifies the contacts made between S2849 and residues that are part of
the last plakin repeat domain (PRD C) in DP. Residues 2802–2805 are shown as van der Waals spheres
on the left, and S2849SPO3 is shown as vdW spheres in the center. These close contacts suggest that the
DPCTT can directly interact with the PRDs.
Table 1: Simulation systems and their CyR∗ histograms. Cy
R
∗ values from the last 100 ns of each
simulation are presented as histograms, where the intensity in a particular bin represents the frequency
that the system had the corresponding CyR∗ value. As an example, the bin numbers are explicitly shown in
, which represents a simulation that frequently displayed CyR∗ values of 2, 3, and 4 (highest peaks
in the histogram). CHARMM36 was consistently found to predict higher CyR∗ values than PARM99SB; in
terms of clawicity, CHARMM36 also predicts a stronger response to phosphorylation.
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Force-field
Simulation system Duration (per FF) PARM99SB CHARMM36
Wild-type, unmodified 100 ns
S2849SPO3 200 ns
R2834H 100 ns
R2834H and S2849SPO3 200 ns
R2834RMe2 100 ns
R2834RMe2 and S2849SPO3 200 ns
S2849SHPO3 (PARM99SB only) 100 ns –
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Overview
This document provides the detailed results of the analysis suite described in the Methods section of the
main text, as applied to each of our simulation systems. Each trajectory has been analyzed in terms of (a)
CyR∗ , (b) CyR, (c) SASA of S2849, (d) SASA of R2834, (e) S2849·····R2834 distance, (f) GSK3 steric clash,
(g) interresidue contact, (h) and backbone dihedral angles.
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(a) CyR∗ (b) CyR (c) SASA of S2849
(d) SASA of R2834 (e) S2849·····S2845 distance (f) GSK3 steric clash
(g) Contact map (h) Ramachandran plot
Figure S1: Behavior of WT_PARM99SB: Time-series plots mark each observation as a blue point and contain a 1-ns running average
as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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(g) Contact map (h) Ramachandran plot
Figure S2: Behavior of WT_CHARMM36: Time-series plots mark each observation as a blue point and contain a 1-ns running average
as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S3: Behavior of S2849S1P_PARM99SB: Time-series plots mark each observation as a blue point and contain a 1-ns running
average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S4: Behavior of S2849S2P_PARM99SB: Time-series plots mark each observation as a blue point and contain a 1-ns running
average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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(g) Contact map (h) Ramachandran plot
Figure S5: Behavior of S2849S2P_PARM99SB_cycle2: Time-series plots mark each observation as a blue point and contain a 1-ns
running average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S6: Behavior of S2849S2P_CHARMM36: Time-series plots mark each observation as a blue point and contain a 1-ns running
average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S7: Behavior of S2849S2P_CHARMM36_cycle2: Time-series plots mark each observation as a blue point and contain a 1-ns
running average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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(g) Contact map (h) Ramachandran plot
Figure S8: Behavior of R2834H_PARM99SB: Time-series plots mark each observation as a blue point and contain a 1-ns running
average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S9: Behavior of R2834H_CHARMM36: Time-series plots mark each observation as a blue point and contain a 1-ns running
average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S10: Behavior of R2834H_S2849S2P_PARM99SB: Time-series plots mark each observation as a blue point and contain a 1-ns
running average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S11: Behavior of R2834H_S2849S2P_PARM99SB_cycle2: Time-series plots mark each observation as a blue point and
contain a 1-ns running average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and
f.
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Figure S12: Behavior of R2834H_S2849S2P_CHARMM36: Time-series plots mark each observation as a blue point and contain a
1-ns running average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S13: Behavior of R2834H_S2849S2P_CHARMM36_cycle2: Time-series plots mark each observation as a blue point and
contain a 1-ns running average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and
f.
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Figure S14: Behavior of R2834MeMe_PARM99SB: Time-series plots mark each observation as a blue point and contain a 1-ns running
average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S15: Behavior of R2834MeMe_CHARMM36: Time-series plots mark each observation as a blue point and contain a 1-ns
running average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S16: Behavior of R2834MeMe_S2849S2P_PARM99SB: Time-series plots mark each observation as a blue point and contain
a 1-ns running average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S17: Behavior of R2834MeMe_S2849S2P_PARM99SB_cycle2: Time-series plots mark each observation as a blue point and
contain a 1-ns running average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and
f.
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Figure S18: Behavior of R2834MeMe_S2849S2P_CHARMM36: Time-series plots mark each observation as a blue point and contain
a 1-ns running average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d, e, and f.
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Figure S19: Behavior of R2834MeMe_S2849S2P_CHARMM36_cycle2: Time-series plots mark each observation as a blue point
and contain a 1-ns running average as a green trace, and the marginal distributions are shown on the right axis, in each of panels a, c, d,
e, and f.
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